Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire E Wainwright

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
The Lancet. Respiratory Medicine|June 15, 2016
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysisJ Stuart Elborn, Bonnie W Ramsey, Michael P Boyle, et al.
Diagnostic Microbiology and Infectious Disease|November 26, 2008
Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genesSnehal N Anuj, David M Whiley, Timothy J Kidd, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 18, 2025
The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studiesIeuan Es Evans, Christine M Duplancic, Timothy A Kidd, et al.
British Journal of Clinical Pharmacology|November 1, 2006
A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patientsStefanie Hennig, Timothy H Waterhouse, Scott C Bell, et al.
Clinical Therapeutics|April 24, 2026
Lumacaftor-Ivacaftor in Pediatric Patients With Cystic Fibrosis and Advanced Liver Disease: A Pilot StudyAdeline Y L Lim, Maria P Hernández-Mitre, Peter J Lewindon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 5, 2018
Differential expression of genes and receptors in monocytes from patients with cystic fibrosisAbdullah A Tarique, Peter D Sly, Diana G Cardenas, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 5, 2025
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftorClaire E Wainwright, Teja Thorat, Sarah Conner, et al.
Journal of Paediatrics and Child Health|July 15, 2005
Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosisHelen M Buntain, Ristan M Greer, Joseph C H Wong, et al.
The Lancet. Respiratory Medicine|June 11, 2018
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyMargaret Rosenfeld, Claire E Wainwright, Mark Higgins, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 21, 2025
Validation of an artificial intelligence-based automated PRAGMA and mucus plugging algorithm in pediatric cystic fibrosisPranali Raut, Yuxin Chen, Ahmad Taleb, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
The Lancet. Respiratory Medicine|June 15, 2016
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysisJ Stuart Elborn, Bonnie W Ramsey, Michael P Boyle, et al.
Diagnostic Microbiology and Infectious Disease|November 26, 2008
Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genesSnehal N Anuj, David M Whiley, Timothy J Kidd, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 18, 2025
The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studiesIeuan Es Evans, Christine M Duplancic, Timothy A Kidd, et al.
British Journal of Clinical Pharmacology|November 1, 2006
A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patientsStefanie Hennig, Timothy H Waterhouse, Scott C Bell, et al.
Clinical Therapeutics|April 24, 2026
Lumacaftor-Ivacaftor in Pediatric Patients With Cystic Fibrosis and Advanced Liver Disease: A Pilot StudyAdeline Y L Lim, Maria P Hernández-Mitre, Peter J Lewindon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 5, 2018
Differential expression of genes and receptors in monocytes from patients with cystic fibrosisAbdullah A Tarique, Peter D Sly, Diana G Cardenas, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 5, 2025
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftorClaire E Wainwright, Teja Thorat, Sarah Conner, et al.
Journal of Paediatrics and Child Health|July 15, 2005
Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosisHelen M Buntain, Ristan M Greer, Joseph C H Wong, et al.
The Lancet. Respiratory Medicine|June 11, 2018
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyMargaret Rosenfeld, Claire E Wainwright, Mark Higgins, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 21, 2025
Validation of an artificial intelligence-based automated PRAGMA and mucus plugging algorithm in pediatric cystic fibrosisPranali Raut, Yuxin Chen, Ahmad Taleb, et al.
Pageof 10